Lisheng Pharmaceutical adjusts stock incentive plan, grants shares

Tianjin Lisheng Pharmaceutical (SZSE:002393) announced the resolutions passed at its 49th meeting of the seventh board of directors, highlighting adjustments to its 2024 restricted stock incentive plan. The number of eligible participants decreased from 150 to 147, due to three individuals' prior stock trading activities after being listed as insiders. Consequently, the board reallocated the forfeited share quotas within the existing participant pool. The total number of restricted shares remains unchanged at 5.77 million, plus a 1.44 million share reserve, for a total of 7.21 million shares granted. The board also approved the initial grant of 5.77 million restricted shares to 147 participants at a price of 10.59 yuan per share, effective February 12, 2025. Further, the meeting approved the revised regulations governing shareholding and trading activities of the company’s directors, supervisors, and senior management.